Cell-Free Fetal DNA (cfDNA)
Non-Invasive Prenatal Testing (NIPT) in Colombia
NIPT screens cell-free fetal DNA circulating in maternal blood from as early as the 10th week of pregnancy. It offers greater than 99% accuracy in detecting Down Syndrome (Trisomy 21), Edwards Syndrome (Trisomy 18), and Patau Syndrome (Trisomy 13) with zero miscarriage risk.
Key Indications
- Pregnant women from week 10 onwards seeking safe, accurate chromosomal screening.
- Maternal age 35 or older at delivery.
- Abnormal first-trimester biochemical serum screening or ultrasound markers (increased nuchal translucency).
- Personal or family history of chromosomal trisomies (Down, Edwards, or Patau syndromes).
- Anxiety reduction through early, non-invasive genetic certainty and fetal sex determination.